6.
Smith T, Bohlke K, Lyman G, Carson K, Crawford J, Cross S
. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(28):3199-212.
DOI: 10.1200/JCO.2015.62.3488.
View
7.
Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I
. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research.... Ann Oncol. 2016; 27(10):1873-8.
DOI: 10.1093/annonc/mdw274.
View
8.
Gibb A, Tribuddharat C, Moore R, Louie T, Krulicki W, Livermore D
. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7). Antimicrob Agents Chemother. 2001; 46(1):255-8.
PMC: 126979.
DOI: 10.1128/AAC.46.1.255-258.2002.
View
9.
Aapro M, Chaplin S, Cornes P, Howe S, Link H, Koptelova N
. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Support Care Cancer. 2023; 31(10):581.
PMC: 10511548.
DOI: 10.1007/s00520-023-08043-4.
View
10.
Levine M, Bramwell V, Pritchard K, Norris B, Shepherd L, Findlay B
. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada.... J Clin Oncol. 1998; 16(8):2651-8.
DOI: 10.1200/JCO.1998.16.8.2651.
View
11.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N
. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2007; 110(3):531-9.
DOI: 10.1007/s10549-007-9744-z.
View
12.
Molineux G
. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004; 10(11):1235-44.
DOI: 10.2174/1381612043452613.
View
13.
Morita F, Hirai Y, Suzuki K, Uehara Y, Mitsuhashi K, Takahashi M
. The First Case of Pseudomonas aeruginosa Bacteremic Pneumonia in a Cancer Patient Receiving Pegfilgrastim. Intern Med. 2017; 56(15):2039-2042.
PMC: 5577083.
DOI: 10.2169/internalmedicine.56.8245.
View
14.
Roche H, Fumoleau P, Spielmann M, Canon J, Delozier T, Serin D
. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006; 24(36):5664-71.
DOI: 10.1200/JCO.2006.07.3916.
View
15.
Kang C, Kim S, Beom Park W, Lee K, Kim H, Kim E
. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005; 49(2):760-6.
PMC: 547233.
DOI: 10.1128/AAC.49.2.760-766.2005.
View
16.
Bodey G, Jadeja L, Elting L
. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985; 145(9):1621-9.
DOI: 10.1001/archinte.145.9.1621.
View
17.
Klastersky J, Paesmans M, Rubenstein E, Boyer M, Elting L, Feld R
. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16):3038-51.
DOI: 10.1200/JCO.2000.18.16.3038.
View
18.
Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L
. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006; 24(25):4129-34.
DOI: 10.1200/JCO.2005.03.9909.
View